These antihyperglycemic agents stimulate insulin secretion and inhibit the release of glucagon from pancreatic islets in a glucose-dependent manner
These apply to Wegovy, Mounjaro, and other GLP-1 medications as a class
Guirguis says combination treatments such as this could offer additive or synergistic effects meaning that patients have a better chance of responding to at least one of the mechanisms and could experience fewer GI side effects as a result of the dual approach
Protein is not a risk factor
not available for commercial use in U.S.), dulaglutide (Trulicity, Eli Lilly), oral semaglutide (Rybelsus, Novo Nordisk) and efpeglenatide (Sanofi) researchers also found that human and exendin-based GLP-1 receptor agonists reduce risk for all-cause mortality, hospitalization for heart failure, and a composite kidney outcome of development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate or increase in creatinine, renal replacement therapy or renal death
